ARS Investment Partners LLC Boosts Stock Holdings in Novo Nordisk A/S $NVO

ARS Investment Partners LLC raised its holdings in Novo Nordisk A/S (NYSE:NVO) by 9.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 168,560 shares of the company’s stock after purchasing an additional 14,644 shares during the period. ARS Investment Partners LLC’s holdings in Novo Nordisk A/S were worth $8,576,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the business. Chancellor Financial Group WB LP purchased a new position in shares of Novo Nordisk A/S in the fourth quarter worth about $225,000. May Hill Capital LLC increased its stake in shares of Novo Nordisk A/S by 188.1% in the fourth quarter. May Hill Capital LLC now owns 24,212 shares of the company’s stock worth $1,232,000 after purchasing an additional 15,808 shares in the last quarter. Burford Brothers Inc. increased its stake in shares of Novo Nordisk A/S by 7.1% in the fourth quarter. Burford Brothers Inc. now owns 10,798 shares of the company’s stock worth $549,000 after purchasing an additional 717 shares in the last quarter. Center for Financial Planning Inc. grew its stake in Novo Nordisk A/S by 186.8% during the fourth quarter. Center for Financial Planning Inc. now owns 2,134 shares of the company’s stock valued at $109,000 after acquiring an additional 1,390 shares in the last quarter. Finally, Stephens Inc. AR grew its stake in Novo Nordisk A/S by 19.2% during the fourth quarter. Stephens Inc. AR now owns 29,946 shares of the company’s stock valued at $1,524,000 after acquiring an additional 4,818 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Deutsche Bank Aktiengesellschaft cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. Wolfe Research assumed coverage on shares of Novo Nordisk A/S in a research note on Thursday, March 26th. They set a “peer perform” rating for the company. Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 24th. Finally, BMO Capital Markets reaffirmed a “market perform” rating on shares of Novo Nordisk A/S in a research note on Thursday, February 5th. Four research analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $44.71 on Friday. The company has a 50 day moving average of $39.73 and a 200 day moving average of $46.69. The stock has a market cap of $199.63 billion, a P/E ratio of 10.50, a P/E/G ratio of 3.98 and a beta of 0.77. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $81.44. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The business had revenue of $10.85 billion during the quarter. As a group, sell-side analysts forecast that Novo Nordisk A/S will post 3.47 EPS for the current fiscal year.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk reported encouraging early data for its oral Wegovy program, with trial results highlighting meaningful weight-loss efficacy and better tolerability, reinforcing confidence in the company’s GLP-1 pipeline. Article Title
• Positive Sentiment: The company’s recent Q1 results beat estimates and it raised its 2026 outlook, suggesting the core business remains resilient despite a tougher competitive environment. Article Title
• Positive Sentiment: Investor commentary is increasingly focused on Novo Nordisk’s restructuring efforts, oral Ozempic/Wegovy launches, and telehealth partnerships, which are being viewed as potential growth drivers. Article Title
• Positive Sentiment: Hims & Hers noted a Novo Nordisk GLP-1 partnership as part of its weight-loss care expansion, underscoring broader commercial adoption of Novo’s obesity treatments. Article Title
• Neutral Sentiment: Several articles discussed Novo Nordisk’s valuation, long-term returns, and stock forecasts, but these were mostly commentary pieces rather than new fundamental developments. Article Title
• Neutral Sentiment: There was also a disclosure about gifted share transactions linked to CFO associates, which appears administrative rather than a major operating issue. Article Title
• Negative Sentiment: Market commentary continues to emphasize competitive pressure from Eli Lilly’s expanding GLP-1 portfolio, raising concerns about Novo Nordisk’s ability to defend its obesity market leadership. Article Title
• Negative Sentiment: One analyst-style piece explicitly argued against upgrading the stock, reflecting skepticism that the recent rebound has fully resolved the company’s longer-term challenges. Article Title

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.